Physician profile
Jonathan M Patton
NPI 1215057559
$2,473.39
in general payments reported to CMS, 2019-2025
26 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $108 · 2021: $254 · 2022: $647 · 2023: $423 · 2024: $537 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,299.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $511.50 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $381.83 | 2019-2025 | Lifevest |
| Amgen INC. | $214.47 | 2020-2024 | Repatha |
| Pfizer INC. | $145.39 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $126.83 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $115.68 | 2022-2024 | Farxiga, Wainua |
| Cardiva Medical, INC. | $95.64 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $90.51 | 2019-2022 | |
| Edwards Lifesciences Corporation | $82.52 | 2022-2025 | Sapien 3 Ultra Resilia |
| Chiesi USA, INC. | $78.50 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.60 | 2021-2024 | Jardiance |
| Abbott Laboratories | $67.55 | 2022-2025 | Amplatzer Amulet, Aveir |
| Abiomed | $61.89 | 2025 | |
| Boston Scientific Corporation | $61.12 | 2021-2024 | Watchman Flx, Emblem Mri S-Icd |
| Sanofi-Aventis U.S. LLC | $58.56 | 2019-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $57.96 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Merck Sharp & Dohme LLC | $47.89 | 2021-2024 | Verquvo |
| Alnylam Pharmaceuticals INC. | $39.78 | 2019-2020 | |
| Vital Connect, INC | $36.33 | 2023 | Vitalpatch Rtm |
| Bayer Healthcare Pharmaceuticals INC. | $19.96 | 2025 | |
| Cardinal Health 200 LLC | $19.44 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $18.90 | 2023 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $17.98 | 2023 | Uptravi, Opsumit |
| Takeda Pharmaceuticals U.S.A., INC. | $17.83 | 2022 | |
| Cvrx, INC. | $14.71 | 2023 | Barostim Neo System |
| Medtronic Vascular, INC. | $13.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Patton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.